• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aligos Therapeutics, Inc. - Common stock (NQ:ALGS)

6.850 -0.220 (-3.11%)
Streaming Delayed Price Updated: 1:40 PM EDT, Aug 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aligos Therapeutics, Inc. - Common stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China
August 12, 2026
From Aligos Therapeutics
Via GlobeNewswire
Keep an eye on the top gainers and losers in Monday's session. ↗
August 10, 2026
Via Chartmill
News headline image
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results
August 06, 2026
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics to Announce 2nd Quarter 2026 Financial Results on August 6, 2026
July 30, 2026
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics (NASDAQ:ALGS) Surges After Hours on Q1 Earnings Beat ↗
May 07, 2026
Via Chartmill
Aligos Therapeutics Inc (NASDAQ:ALGS) Reports Q4 Revenue Miss, Highlights 2026 Clinical Catalysts ↗
March 05, 2026
Via Chartmill
News headline image
Earnings Scheduled For November 6, 2025 ↗
November 06, 2025
 
Via Benzinga
News headline image
Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection
July 13, 2026
Topline data expected to be available late 3Q2027 
From Aligos Therapeutics
Via GlobeNewswire
The trading volume of these stocks is deviating from the norm in today's session. ↗
July 08, 2026
Via Chartmill
Monday's after hours session: top gainers and losers ↗
July 06, 2026
Via Chartmill
News headline image
Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection
July 06, 2026
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Presents Positive Data at the EASL Congress 2026
May 27, 2026
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026
May 13, 2026
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results
May 07, 2026
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026
April 30, 2026
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 24, 2026
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection
April 16, 2026
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation
April 14, 2026
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results
March 05, 2026
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics to Announce 4th Quarter 2025 Financial Results on March 5, 2026
February 26, 2026
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Presents Positive Data at the Conference on Retroviruses and Opportunistic Infections (CROI)
February 23, 2026
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 30, 2026
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates
January 21, 2026
Interim analyses on track for the first and second half of 2026 
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of James Hassard as Executive Vice President, Chief Commercial Officer
January 13, 2026
Seasoned leader with global commercialization and marketing expertise 
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 12, 2025
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Presents Positive Data at HEP-DART 2025
December 11, 2025
Oral presentation of ALG-055009 in vivo nonclinical data showcases synergistic fat mass loss in combination with incretin receptor agonists 
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 14, 2025
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2025
November 10, 2025
Oral presentation of 96-week treatment and post-treatment data suggest best-in-class potential of pevifoscorvir sodium 
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results
November 06, 2025
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics to Present at Upcoming Investor Conferences
November 04, 2025
From Aligos Therapeutics
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap